New targeted drug enters first human tests for Hard-to-Treat cancers
NCT ID NCT06597721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to find the safest dose and to see if the drug is tolerable, with early signs of tumor shrinkage also being monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADCE-T02 (an antibody-drug conjugate targeting tissue factor)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early phase 1 trial focused on safety and dosing, so it is uncertain if ADCE-T02 will effectively shrink tumors or have manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Cabrini Hospital
RECRUITINGMalvern, Victoria, 3144, Australia
-
Highlands Oncology Group
RECRUITINGRogers, Arkansas, 72758, United States
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Macquarie University Hospital
RECRUITINGMacquarie Park, New South Wales, 2109, Australia
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Peninsula and South Eastern Haematology and Oncology Group (PSEHOG)
RECRUITINGFrankston, Victoria, 3199, Australia
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
Scientia Clinical Research
RECRUITINGRandwick, New South Wales, 2031, Australia
-
Southern Oncology Clinical Research Unit
RECRUITINGBedford Park, South Australia, 5042, Australia
-
Yale University Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States